Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18632/oncotarget.12791 http://scihub22266oqcxt.onion/10.18632/oncotarget.12791 C5348384!5348384 !27783987     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27783987 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Oncotarget 2016 ; 7 (49 ): 81172-81186 Nephropedia Template TP {{tp|p=27783987 |t=2016. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma |pdf=|usr=}}{{27783987 }} gab.com Text The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma JO: Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=27783987 #FOAvip The ubiquitin-proteasome signaling pathway is critical for cell cycle regulation and neoplastic growth. Proteasome inhibition can activate apoptotic pathways. Bortezomib, a selective proteasome inhibitor, has anti-melanoma activity. MLN2238 (ixazomib), an oral proteasome inhibitor, has improved pharmacotherapeutic parameters compared to bortezomib. Interferon-alpha (IFN-?), an immune boosting agent, is FDA-approved for treatment of melanoma. In this study in vitro and in vivo evaluation of the antitumor potential of ixazomib and combination treatments with ixazomib and IFN-? were performed. Apoptosis induced by ixazomib was first observed at 12 hours and was maximal at 48 hours with similar levels of cell death compared to bortezomib. IFN-? alone had little effect on cell viability in vitro. However, the combination of ixazomib with IFN-? significantly enhanced ixazomib's ability to induce apoptotic cell death in BRAF V600E mutant and BRAF wild-type human melanoma tumor cells. The combination of ixazomib and IFN-? also enhanced inhibition of cell proliferation in BRAF V600E mutant melanoma tumor cells; however, this was not seen in BRAF wild-type cells. Ixazomib-induced apoptosis was associated with processing of the pro-apoptotic proteins procaspase-3, -7, -8, and -9, and cleavage of poly-ADP-ribose polymerase (PARP). In an in vivo xenograft model of human melanoma, combination treatment with IFN-?-2b and ixazomib demonstrated a significant reduction in tumor volume when compared to vehicle (p = 0.005) and single therapy ixazomib (p = 0.017) and IFN-?-2b (p = 0.036). These pre-clinical results support further evaluation of combination treatment with ixazomib and IFN-? for the treatment of advanced BRAF V600E mutant melanoma. Twit Text FOAVip The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma ????Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=27783987 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27783987 #FOAvip English Wikipedia <ref>{{Cite pmid|27783987 }}</ref> The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma #MMPMID27783987 Suarez-Kelly LP ; Kemper GM ; Duggan MC ; Stiff A ; Noel TC ; Markowitz J ; Luedke EA ; Yildiz VO ; Yu L ; Jaime-Ramirez AC ; Karpa V ; Zhang X ; Carson WE 3rd Oncotarget 2016[Dec]; 7 (49 ): 81172-81186 PMID27783987 show ga The ubiquitin-proteasome signaling pathway is critical for cell cycle regulation and neoplastic growth. Proteasome inhibition can activate apoptotic pathways. Bortezomib, a selective proteasome inhibitor, has anti-melanoma activity. MLN2238 (ixazomib), an oral proteasome inhibitor, has improved pharmacotherapeutic parameters compared to bortezomib. Interferon-alpha (IFN-?), an immune boosting agent, is FDA-approved for treatment of melanoma. In this study in vitro and in vivo evaluation of the antitumor potential of ixazomib and combination treatments with ixazomib and IFN-? were performed. Apoptosis induced by ixazomib was first observed at 12 hours and was maximal at 48 hours with similar levels of cell death compared to bortezomib. IFN-? alone had little effect on cell viability in vitro. However, the combination of ixazomib with IFN-? significantly enhanced ixazomib's ability to induce apoptotic cell death in BRAF V600E mutant and BRAF wild-type human melanoma tumor cells. The combination of ixazomib and IFN-? also enhanced inhibition of cell proliferation in BRAF V600E mutant melanoma tumor cells; however, this was not seen in BRAF wild-type cells. Ixazomib-induced apoptosis was associated with processing of the pro-apoptotic proteins procaspase-3, -7, -8, and -9, and cleavage of poly-ADP-ribose polymerase (PARP). In an in vivo xenograft model of human melanoma, combination treatment with IFN-?-2b and ixazomib demonstrated a significant reduction in tumor volume when compared to vehicle (p = 0.005) and single therapy ixazomib (p = 0.017) and IFN-?-2b (p = 0.036). These pre-clinical results support further evaluation of combination treatment with ixazomib and IFN-? for the treatment of advanced BRAF V600E mutant melanoma. |Animals [MESH] |Antineoplastic Combined Chemotherapy Protocols/*pharmacology [MESH] |Apoptosis Regulatory Proteins/metabolism [MESH] |Apoptosis/*drug effects [MESH] |Boron Compounds/*pharmacology [MESH] |Cell Line, Tumor [MESH] |Cell Proliferation/drug effects [MESH] |Dose-Response Relationship, Drug [MESH] |Female [MESH] |Glycine/*analogs & derivatives/pharmacology [MESH] |Humans [MESH] |Interferon alpha-2 [MESH] |Interferon-alpha/*pharmacology [MESH] |Melanoma/*drug therapy/enzymology/genetics/pathology [MESH] |Mice, Inbred BALB C [MESH] |Mice, Nude [MESH] |Mutation [MESH] |Proteasome Endopeptidase Complex/*drug effects/metabolism [MESH] |Proteasome Inhibitors/*pharmacology [MESH] |Proto-Oncogene Proteins B-raf/genetics [MESH] |Recombinant Proteins/pharmacology [MESH] |Skin Neoplasms/*drug therapy/enzymology/genetics/pathology [MESH] |Time Factors [MESH] |Tumor Burden/drug effects [MESH]The combination of MLN2238 (ixazomib) with interferon-alpha results in(epmc).pdf DeepDyve Pubget Overpricing